2016

Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial

Christopher Parker
Royal Marsden Hospital, London

Steven E. Finkelstein
Cancer Treatment Centers of America, Tulsa

Jeff M. Michalski
Washington University School of Medicine in St. Louis

Joe M. O'Sullivan
Queen's University Belfast

Oyvind Bruland
Norwegian Radium Hospital, Oslo

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Parker, Christopher; Finkelstein, Steven E.; Michalski, Jeff M.; O'Sullivan, Joe M.; Bruland, Oyvind; Vogelzang, Nicholas J.; Coleman, Robert E.; Nilsson, Sten; Sartor, Oliver; Li, Rui; Seger, Monica A.; and Bottomley, David, "Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial." European Urology.70,5, 875-883. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/6511
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial

Christopher Parker, Steven E. Finkelstein, Jeff M. Michalski, Joe M. O’Sullivan, Øyvind Bruland, Nicholas J. Vogelzang, Robert E. Coleman, Sten Nilsson, Oliver Sartor, Rui Li, Monica A. Seger, David Bottomley

Royal Marsden Hospital, Sutton, London, UK; Cancer Treatment Centers of America, Tulsa, OK, USA; Washington University School of Medicine, St Louis, MO, USA; Center for Cancer Research and Cell Biology, Queen’s University, Belfast, UK; Norwegian Radium Hospital, Oslo, Norway; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; University of Sheffield, Sheffield, South Yorkshire, UK; Karolinska University Hospital, Stockholm, Sweden; Tulane Cancer Center, New Orleans, LA, USA; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA; St. James University Hospital, Leeds, Yorkshire, UK

Article info
Article history: Accepted June 3, 2016
Associate Editor: James Catto

Abstract

Background: The phase 3 ALSYMPCA trial enrolled metastatic castration-resistant prostate cancer patients with or without baseline opioid use.

Objective: To assess the efficacy and safety of radium-223 dichloride (radium-223) versus placebo in ALSYMPCA patients by baseline opioid use.

Design, setting, and participants: Nine hundred and twenty one patients enrolled at 136 centers globally.

Intervention: Radium-223 (50 kBq/kg, intravenous injection) every 4 wk for six cycles or matching placebo, each plus best standard of care.

Outcome measurements and statistical analysis: Primary endpoint (overall survival [OS]), main secondary efficacy endpoints, and safety were evaluated by baseline opioid use. Additional analyses included time to first opioid use, time to first external beam radiation therapy for bone pain, and safety of concomitant external beam radiation therapy.

Results and limitations: At baseline, 408 (44%) patients had no pain and no analgesic use or mild pain with nonopioid therapy (World Health Organization ladder pain score 0–1 [non-opioid subgroup]), and 513 (56%) had moderate pain with occasional opioids or severe pain with regular daily opioids (World Health Organization ladder pain score 2–3 [opioid subgroup]). Radium-223 significantly prolonged OS versus placebo in nonopioid (hazard ratio [HR] = 0.70; 95% confidence interval [CI]: 0.52–0.93; \( p = 0.013 \)) and opioid (HR = 0.68; 95% CI: 0.54–0.86; \( p = 0.001 \)) subgroups, and significantly reduced risk of symptomatic skeletal events versus placebo, regardless of baseline opioid use (nonopioid subgroup: HR = 0.56, 95% CI: 0.39–0.82, \( p = 0.002 \); opioid subgroup: HR = 0.72, 95% CI: 0.53–0.98, \( p = 0.038 \)). Time to first opioid use for bone pain was significantly delayed with radium-223 versus placebo (HR = 0.62, 95% CI: 0.46–0.85, \( p = 0.002 \)). Adverse event incidences were similar between opioid subgroups.

Conclusions: Radium-223 versus placebo significantly prolonged OS and reduced symptomatic skeletal event risk with a favorable safety profile in castration-resistant prostate cancer patients with symptomatic bone metastases, regardless of baseline opioid use.

Patient summary: In this ALSYMPCA opioid subgroup analysis, baseline symptom levels did not appear to impact radium-223 dichloride efficacy or safety.

© 2016 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Radium-223 dichloride (radium-223), a first-in-class alpha-emitting radiopharmaceutical [1–3], has demonstrated survival benefits for patients with symptomatic bone metastases from castration-resistant prostate cancer (CRPC). In the randomized phase 3 ALSYMPCA study, radium-223 plus best standard of care (BSoC) versus placebo plus BSoC prolonged median overall survival (OS) by 3.6 mo (hazard ratio [HR] = 0.70; 95% confidence interval [CI]: 0.58–0.83; p < 0.001; median 14.9 mo vs 11.3 mo, respectively) and prolonged median time to first symptomatic skeletal event (SSE) by 5.8 mo (HR = 0.66; 95% CI: 0.52–0.83; p < 0.001; median 15.6 mo vs 9.8 mo, respectively) in patients with CRPC and symptomatic bone metastases [4,5]. Additionally, radium-223 had a favorable safety profile with a low myelosuppression rate [4]. ALSYMPCA results led to radium-223 approval for the treatment of CRPC patients with symptomatic bone metastases and no known visceral metastatic disease [6].

Unlike the phase 2 radium-223 dose-response pain study [7], ALSYMPCA was not designed to evaluate the effect of radium-223 on pain; the primary endpoint was OS, and all patients received BSoC during the study, including treatments to manage pain (eg, external beam radiation therapy [EBRT], analgesics) [4]. ALSYMPCA eligibility required having symptomatic disease, broadly defined to include patients with regular use of analgesic medication (non-opioid or opioid) or pain-free patients who received EBRT for cancer-related bone pain in the 12 wk before randomization [4]. At baseline, 44% of radium-223 and 45% of placebo patients had no pain or had mild pain effectively managed without need for opioids; the remaining patients (56% radium-223 and 55% placebo) required opioids at study entry [4].

The efficacy and favorable safety of radium-223 was observed in the overall ALSYMPCA population that included patients both with and without baseline opioid use. The question arises of whether the radium-223 survival advantage depended on patients’ baseline symptom severity. In other words, would patients with no or minimal symptoms benefit from radium-223 as much as those with symptoms? To address this question, we assessed the efficacy and safety of radium-223 versus placebo in ALSYMPCA patients who did not require opioid therapy at baseline (ie, minimally symptomatic disease) versus those receiving opioids at baseline (ie, symptomatic disease). Additional analyses assessed the impact of radium-223 on delaying the need for opioids or EBRT for bone pain management and the safety of concomitant EBRT.

2. Patients and methods

2.1. Patients and study design

ALSYMPCA was a phase 3, randomized, double-blind, placebo-controlled study conducted at 136 centers in 19 countries to compare the efficacy and safety of radium-223 plus BSoC versus placebo plus BSoC in CRPC patients with symptomatic bone metastases. Patient eligibility criteria were previously reported [4,5,8]. Briefly, eligible patients had histologically confirmed, progressive CRPC, at least two bone metastases, no known visceral metastases, and symptomatic disease defined as regular use of nonopioid analgesics or opioid medication for cancer-related bone pain (World Health Organization [WHO] ladder pain score ≥ 1) or EBRT for cancer-related bone pain in the 12 wk prior to randomization.

Patients were randomized (2:1) to receive either six intravenous injections of radium-223 50 kBq/kg (55 kBq/kg following the National Institute of Standards and Technology update [9]) or matching placebo, one injection every 4 wk. Patients were stratified by previous docetaxel use (yes or no), baseline total alkaline phosphatase (tALP) serum level (≤220 U/l or ≥220 U/l), and bisphosphonate use at study entry (yes or no). All patients received BSoC available at each center (Supplementary Table 1). The planned follow-up was 3 yr from first study-drug injection. Review boards at all participating centers approved the study, and all patients provided written informed consent. The study was registered with ClinicalTrials.gov, number NCT00699751.

2.2. Procedures

Opioids were permitted prior to and during ALSYMPCA, but were not a requirement for study entry. Investigators were free to manage bone pain during the study by starting nonopioid analgesics, or adding EBRT or opioids to pre-existing nonopioid analgesics as recommended by the WHO guidelines [10]. EBRT could be administered at any time prior to randomization or within 12 wk prior to randomization to fulfill the eligibility requirement of symptomatic disease and was allowed during the study as part of BSoC. Time to first EBRT use for bone pain was documented as a component of the secondary endpoint time to first SSE.

2.3. Opioid subgroups and study assessments

This analysis was designed to assess radium-223 efficacy and safety in the subgroups of patients who had or had not received opioids at baseline. Two subgroups were defined: the nonopioid subgroup included patients with no pain and no analgesic use (WHO ladder pain score 0) or mild pain and no opioid use (WHO ladder pain score 1) at baseline; the opioid subgroup included patients with moderate pain and occasional opioid use (WHO ladder pain score 2) or severe pain and regular daily opioid use (WHO ladder pain score 3) at baseline.

2.4. Outcomes

Patient outcomes by baseline opioid use and treatment group were evaluated for the ALSYMPCA primary endpoint (OS), main secondary efficacy endpoints, and safety. OS was defined as time from randomization to date of death, regardless of cause. Main secondary efficacy endpoints were time to first SSE (defined as first EBRT use to relieve bone pain, or occurrence of new symptomatic pathologic bone fractures [vertebral or nonvertebral], spinal cord compression, or tumor-related orthopedic surgical intervention); time to prostate-specific antigen (PSA)-level increase; time to tALP-level increase; confirmed ≥30% reduction in tALP response; and tALP normalization. The initial trial report contains a complete description of these efficacy and safety endpoints [4].

2.5. Statistical analyses

Analyses of OS by opioid subgroup and time to first EBRT use for bone pain were specified in the protocol and included in the original planned analysis. Subsequent, exploratory analyses included the main secondary efficacy endpoints by opioid subgroup, safety by opioid subgroup, time to first use of opioids, and safety with concomitant EBRT. All data were prospectively collected.
Efficacy analyses for opioid subgroups were based on the intent-to-treat (ITT) population, including all randomized patients. Safety analyses were based on the safety population, including all patients who received at least one study-drug injection. A log-rank test was used to analyze OS and main secondary efficacy endpoints of time to first SSE, time to tALP increase, and time to PSA increase. HRs were estimated using the Cox proportional hazards regression model. Both the log-rank test and the Cox model were stratified by tALP, bisphosphonate use at study entry, and prior docetaxel use. An unstratified Cox proportional hazards model was used to test the treatment by opioid subgroup interaction. Median values for time-to-event variables (OS, time to first SSE, time to tALP increase, time to PSA increase, time to first opioid use, and time to first EBRT) were assessed using the Kaplan-Meier method and censored at the last known alive date or patient assessment date, if an event had not occurred at time of analysis or the patient was lost to follow-up. tALP response and normalization were analyzed using a Cochran-Mantel-Haenszel analysis adjusting for stratification factors tALP, current bisphosphonate use, and prior docetaxel use. Safety analyses were descriptive.

Additional analyses evaluated the radium-223 effect on addition of opioids or need for EBRT. Time to first on-study opioid use was assessed in patients not receiving opioids at baseline (ie, nonopioid subgroup). Time to first EBRT use for bone pain was a component of the SSE main secondary efficacy endpoint and was assessed in the overall ALSYMPCA ITT population. Adverse events (AEs) by concomitant EBRT were analyzed in the ALSYMPCA safety population.

3. Results

3.1. Nonopioid and opioid subgroups

Of the 921 patients randomized in the ALSYMPCA ITT population, 408 (44%) had no pain and no analgesic use (WHO ladder pain score 0) or mild pain managed with nonopioid therapy (WHO ladder pain score 1) at baseline (nonopioid subgroup: radium-223, \( n = 269 \); placebo, \( n = 139 \)), and 513 (56%) had moderate pain with occasional opioids (WHO ladder pain score 2) or severe pain with regular daily opioids (WHO ladder pain score 3) at baseline (opioid subgroup: radium-223, \( n = 345 \); placebo, \( n = 168 \); Fig. 1). In the nonopioid subgroup, 12 of 269 (4%) radium-223 patients and two of 139 (1%) placebo patients...
were completely pain free, although they met the study inclusion criteria for symptomatic disease, having received EBRT in the 12 wk prior to randomization.

### 3.2. Patient demographics and baseline characteristics

Demographics and baseline characteristics were generally balanced between nonopioid and opioid subgroups and the overall ALSYMPCA ITT population (Table 1). Compared with radium-223 patients who required opioids, those in the nonopioid subgroup appeared to have less advanced disease, suggested by a greater proportion with TALP values <220 U/l, lower median TALP and lactate dehydrogenase values, better performance status, and less extensive skeletal disease. Also, fewer had prior docetaxel therapy and EBRT for pain in the 12 wk prior to randomization. A similar trend was seen among placebo patients (Table 1). Irrespective of treatment allocation, the survival duration and time to first SSE were longer in minimally symptomatic (i.e., WHO ladder pain score 0–1/without opioid use) than in more symptomatic patients (i.e., WHO ladder pain score 2–3/with opioid use).

#### 3.3. Efficacy: survival

Radium-223 significantly prolonged OS, regardless of baseline opioid use. Consistent OS benefits were seen with radium-223 treatment versus placebo in nonopioid (HR = 0.70; 95% CI: 0.52–0.93; p = 0.013; median 16.4 mo vs 12.8 mo, respectively) and opioid (HR = 0.68; 95% CI: 0.54–0.86; p = 0.001; median 13.9 mo vs 10.4 mo, respectively) subgroups (Fig. 2, A and B). The treatment by opioid subgroup interaction was not statistically significant (p = 0.985), indicating that there is no difference in treatment effect between the opioid and nonopioid subgroups for OS.

#### 3.4. Efficacy: SSE and other main secondary efficacy endpoints

Radium-223 treatment significantly reduced the risk of SSEs compared with placebo, regardless of baseline opioid use (nonopioid subgroup: HR = 0.56, 95% CI: 0.39–0.82, p = 0.002; opioid subgroup: HR = 0.72, 95% CI: 0.53–0.98, p = 0.038; (Fig. 2, C and D). Additionally, all main secondary efficacy endpoints were met, regardless of baseline opioid use (Table 2).

### Table 1 – Patient demographics and baseline characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Nonopioid subgroup</th>
<th>Opioid subgroup</th>
<th>ITT population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Radium-223 n = 269</td>
<td>Placebo n = 139</td>
<td>Radium-223 n = 345</td>
</tr>
<tr>
<td>Age Median, yr</td>
<td>72 (51–90)</td>
<td>73 (50–89)</td>
<td>71 (49–88)</td>
</tr>
<tr>
<td>Total alkaline phosphatase level, n (%)</td>
<td>&lt;220 U/l 169 (63) 82 (59) 179 (52) 87 (52) 348 (57) 169 (55)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current use of bisphosphonates, n (%)</td>
<td>Yes 105 (39) 57 (41) 145 (42) 67 (40) 250 (41) 124 (40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior use of docetaxel, n (%)</td>
<td>No 164 (61) 82 (59) 200 (58) 101 (60) 364 (59) 183 (60)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHO ladder for cancer pain, n (%)</td>
<td>0 99 (37) 44 (32) 66 (19) 34 (20) 165 (27) 78 (25)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG performance status score, n (%)</td>
<td>1 151 (56) 84 (60) 220 (64) 103 (61) 371 (60) 187 (61)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EXTENT of disease, n (%)</td>
<td>2 18 (7) 11 (8) 59 (17) 30 (18) 77 (13) 41 (13)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHO ladder for cancer pain, n (%)</td>
<td>0 (no pain; no opioid use) 12 (4) 2 (1) 0 0 12 (2) 2 (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG performance status score, n (%)</td>
<td>1 (mild pain; no opioid use) 257 (96) 137 (99) 0 0 257 (42) 137 (45)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior use of docetaxel, n (%)</td>
<td>2 (moderate pain; occasional opioid use) 0 0 151 (44) 78 (46) 151 (25) 78 (25)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG performance status score, n (%)</td>
<td>3 (severe pain; regular daily opioid use) 0 0 194 (56) 90 (54) 194 (32) 90 (29)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBRT to bone &gt;12 wk prior to randomization, n (%)</td>
<td>33 (12) 20 (14) 66 (19) 28 (17) 99 (16) 48 (16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median biochemical values (range)</td>
<td>Hemoglobin (g/dl) 13 (9–16) 13 (9–16) 12 (9–15) 12 (9–16) 12 (9–16) 12 (9–16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Albumin (g/l) 40 (26–53) 40 (24–50) 40 (24–52) 40 (23–49) 40 (24–53) 40 (23–50)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total alkaline phosphatase (U/l) 164 (32–6431) 213 (29–3225) 240 (40–2727) 235 (36–4805) 211 (32–6431) 223 (29–4805)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prostate-specific antigen (ng/ml) 145 (4–5790) 165 (2–4850) 151 (4–6026) 173 (7–14500) 146 (4–6026) 173 (2–14500)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**EBRT** = external beam radiation therapy; **ECOG** = Eastern Cooperative Oncology Group; **ITT** = intent-to-treat; **radium-223** = radium-223 dichloride; **WHO** = World Health Organization.

* Percentages may not sum to 100 due to rounding.

b Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.

¢ The normal biochemical ranges are as follows: hemoglobin, 13–17 g/dl; albumin, 36–45 g/l; total alkaline phosphatase, 35–105 U/l; lactate dehydrogenase, 115–255 U/l; and prostate-specific antigen, 0–3.999 μg/l.
Fig. 2 – Kaplan-Meier estimates of (A, B) overall survival and (C, D) time to first symptomatic skeletal event by baseline opioid use (intent-to-treat population; N = 921); and (E) time to first opioid use in patients without baseline opioid use (nonopioid subgroup, n = 408).

CI = confidence interval; HR = hazard ratio; radium-223 = radium-223 dichloride; SSE = symptomatic skeletal event.

* Median time to first symptomatic skeletal event in the nonopioid subgroup was longer for placebo patients versus radium-223 patients (19.5 mo vs 17.1 mo, respectively), as few patients were left in the placebo group toward the end of the assessment period and the curves crossed before median time to first symptomatic skeletal event was reached, thus the tail end of the curves were not reliably estimated. The 25th percentile was 8.3 mo for radium-223 patients and 5.2 mo for placebo patients, indicating the treatment benefit of radium-223 during the early part of the study, when most patients were evaluable. Hazard ratio is the most appropriate statistical parameter to best interpret the treatment difference over the entire observed time frame.
3.5. Safety

No clinically meaningful treatment differences in the incidence of hematologic or nonhematologic AEs were observed between nonopioid and opioid subgroups (Table 3), despite the slightly higher AE incidence (all grades and Grade 3/4) in the opioid subgroup for radium-223 and placebo patients, which may reflect more advanced disease in these patients. Although rare, Grades 3/4 neutropenia and thrombocytopenia occurred more frequently in radium-223 patients versus placebo patients, regardless of opioid subgroup (nonopioid subgroup: neutropenia in 2% vs 1%, thrombocytopenia in 5% vs 1%; opioid subgroup: neutropenia in 2% vs 1%, thrombocytopenia in 7% vs 2%; Table 3).

3.6. Radium-223 with concomitant opioids or EBRT for bone pain management

As mentioned above, opioids and EBRT were permitted as part of BSoC for bone pain management. Time to first use of opioids for bone pain was assessed in patients not receiving baseline opioids (ie, nonopioid subgroup). During the study, opioids were required by 36% (96/269) of radium-223 patients versus 50% (70/139) of placebo patients who were not receiving opioids at baseline. Radium-223 significantly delayed time to first opioid use for bone pain versus placebo (HR = 0.62, 95% CI: 0.46–0.85, p = 0.002; median not estimable vs 6.9 mo, respectively; Fig. 2E).

During the study, 30% (186/614) of radium-223 patients and 34% (105/307) of placebo patients received EBRT for bone pain. Radium-223 significantly reduced the risk of needing EBRT for bone pain by 33% versus placebo (HR = 0.67, 95% CI: 0.53–0.85, p = 0.001; Supplementary Fig. 1). No differences were seen in the safety profile between patients who did and did not receive concomitant EBRT for bone pain during the study (Table 4). Additionally, myelosuppression rates were low regardless of concomitant EBRT.

4. Discussion

In ALSYMPCA, patients were required to have symptomatic disease to be eligible for the study; however, symptomatic was broadly defined, in that opioid use was not required and patients were defined as minimally symptomatic if they had regular use of any analgesic medication or if they had received EBRT in the 12 wk before randomization. This opioid subgroup analysis was conducted to determine if the radium-223 survival advantage in the overall ALSYMPCA
Table 2 – Efficacy endpoints (intent-to-treat population; N = 921)

<table>
<thead>
<tr>
<th></th>
<th>Radium-223 n = 269</th>
<th>Placebo n = 139</th>
<th>Hazard ratioa (95% CI)</th>
<th>p valueb</th>
<th>Radium-223 n = 345</th>
<th>Placebo n = 168</th>
<th>Hazard ratioa (95% CI)</th>
<th>p valueb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary endpoint</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall survival (mo)</td>
<td>16.4 (14.4–18.4)</td>
<td>12.8 (11.3–16.0)</td>
<td>0.70 (0.52–0.93)</td>
<td>0.013</td>
<td>13.9 (11.9–15.4)</td>
<td>10.4 (8.7–11.6)</td>
<td>0.68 (0.54–0.86)</td>
<td>0.001</td>
</tr>
<tr>
<td>Median (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Main secondary efficacy endpoints

| Patients experiencing an event, n (%) | 77 (29) | 50 (36) | 0.56 (0.39–0.82) | 0.002    | 125 (36) | 66 (39) | 0.72 (0.53–0.98) | 0.038    |
| Time to first SSE (mo), median (95% CI) | 17.1 (14.7–NE) | 19.5 (7.9–23.7) | 0.17 (0.11–0.25) | <0.001   | 12.9 (11.0–18.3) | 7.9 (6.2–29.0) | 0.15 (0.11–0.22) | <0.001   |

| Patients with ≥30% reduction in tALP response, n (%) | 168 (62) | 94 (68) | 0.68 (0.53–0.89) | 0.004    | 220 (64) | 99 (59) | 0.62 (0.48–0.80) | <0.001   |
| Time to increase in tALP level (mo), median (95% CI) | 7.4 (7.1–NE) | 4.1 (3.6–4.3) | NE | 3.7 (3.5–4.1) | 4.1 (3.6–4.3) | NE | 3.7 (3.5–4.1) | 4.1 (3.6–4.3) |

| Patients with ≥50% reduction in PSA level (mo), median (95% CI) | 97/225 (43) | 4/102 (4) | NA | <0.001d | 136/272 (50) | 3/109 (3) | NA | <0.001d |
| Time to increase in PSA level (mo), median (95% CI) | 3.6 (3.5–4.0) | 3.5 (3.3–3.5) | 3.6 (3.5–3.9) | 3.4 (3.3–3.5) | 3.6 (3.5–4.0) | 3.5 (3.3–3.5) | 3.6 (3.5–3.9) | 3.4 (3.3–3.5) |

| Patients with normalization of tALP level, n (%) | 51/131 (39) | 0/65 (0) | NA | <0.001d | 58/190 (31) | 2/75 (3) | NA | <0.001d |

CI = confidence interval; NE = not applicable; PSA = prostate-specific antigen; radium-223 = radium-223 dichloride; SSE = symptomatic skeletal event; tALP = total alkaline phosphatase.

a Hazard ratio (radium-223: placebo) is from a Cox proportional hazards model stratified by tALP, current use of bisphosphonates, and prior use of docetaxel.
b Unless otherwise noted, the p value is from the log-rank test stratified by tALP, current use of bisphosphonates, and prior use of docetaxel.
c Grade 3 Grade 4 All grades occurring in ≥5% of patients in either treatment subgroup.

Table 3 – Adverse events (AEs) by opioid subgroup (safety population; N = 901)

<table>
<thead>
<tr>
<th>No. of patients with an AE, n (%)</th>
<th>Radium-223 n = 263</th>
<th>Placebo n = 138</th>
<th>Radium-223 n = 337</th>
<th>Placebo n = 163</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematologic AEsa</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemiaab</td>
<td>69 (26)</td>
<td>26 (10)</td>
<td>4 (2)</td>
<td>38 (28)</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>12 (5)</td>
<td>4 (2)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>11 (4)</td>
<td>4 (2)</td>
<td>1 (&lt;1)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>27 (10)</td>
<td>9 (3)</td>
<td>5 (2)</td>
<td>6 (4)</td>
</tr>
<tr>
<td>Nonhematologic AEd</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>46 (17)</td>
<td>2 (1)</td>
<td>0</td>
<td>26 (19)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>70 (27)</td>
<td>3 (1)</td>
<td>0</td>
<td>27 (20)</td>
</tr>
<tr>
<td>Nausea</td>
<td>79 (30)</td>
<td>4 (2)</td>
<td>0</td>
<td>39 (28)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>42 (16)</td>
<td>5 (2)</td>
<td>0</td>
<td>15 (11)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>63 (24)</td>
<td>5 (2)</td>
<td>2 (1)</td>
<td>33 (24)</td>
</tr>
<tr>
<td>Peripheral edema</td>
<td>26 (10)</td>
<td>2 (1)</td>
<td>0</td>
<td>14 (10)</td>
</tr>
<tr>
<td>Weight decreased</td>
<td>25 (10)</td>
<td>3 (1)</td>
<td>0</td>
<td>19 (14)</td>
</tr>
<tr>
<td>Anemia</td>
<td>38 (14)</td>
<td>4 (2)</td>
<td>0</td>
<td>25 (18)</td>
</tr>
<tr>
<td>Bone pain</td>
<td>111 (42)</td>
<td>35 (13)</td>
<td>2 (1)</td>
<td>82 (59)</td>
</tr>
<tr>
<td>Malignant neoplasm progressiona</td>
<td>25 (10)</td>
<td>2 (1)</td>
<td>1 (&lt;1)</td>
<td>13 (9)</td>
</tr>
</tbody>
</table>

radium-223 = radium-223 dichloride.
a All grades occurring in ≥5% of patients in either treatment subgroup.
b Grade 5 anemia occurred in one (1%) patient in the placebo group (nonopioid subgroup).
c Grade 5 thrombocytopenia occurred in one (<1%) patient in the radium-223 group (nonopioid subgroup); this was considered possibly drug related by the investigator, and the patient died from pneumonia with no evidence of bleeding.
d All grades occurring in ≥15% of patients in either treatment subgroup.
e Grade 5 malignant neoplasm progression occurred in 17 (7%) patients in the radium-223 group and eight (6%) patients in the placebo group (nonopioid subgroup) and in 38 (11%) patients in the radium-223 group and 25 (15%) patients in the placebo group (opioid subgroup).
Additionally, radium-223 treatment has been shown to combination use with other life-prolonging therapies. Select use with other life-prolonging therapies may optimize treatment outcome and allow sequencing or disease course, when patients are minimally symptomatic, radium-223 therapy. Using radium-223 earlier in the disease course, when patients are minimally symptomatic, may optimize treatment outcome and allow sequencing or combination use with other life-prolonging therapies. Additionally, radium-223 treatment has been shown to reduce hospitalization costs versus placebo.

Results from these opioid subgroup analyses showed that radium-223 is effective and well tolerated in both minimally symptomatic nonopioid patients (ie, WHO ladder pain score 0–1/without opioid use) and patients with more advanced symptomatic disease (ie, WHO ladder pain score 2–3/with opioid use). Results from these opioid subgroup analyses showed that radium-223 is effective and well tolerated in both minimally symptomatic nonopioid patients (ie, WHO ladder pain score 0–1/without opioid use) and patients with more advanced symptomatic disease (ie, WHO ladder pain score 2–3/with opioid use).

## 5. Conclusions

Radium-223 compared with placebo improved OS and reduced the risk of initial SSE with a favorable safety profile in patients with CRPC and symptomatic bone metastases, regardless of baseline opioid use. These results show that radium-223 is effective and well tolerated in both minimally symptomatic nonopioid patients (WHO ladder pain score 0–1) and patients with more advanced symptomatic disease who required opioid therapy (WHO ladder pain score 2–3) at baseline. This suggests that symptom severity should not be the basis for determining appropriate timing of radium-223 treatment.

This paper was presented in part at the 2013 Annual Meeting of the American Society of Clinical Oncology, May 31st to June 4th, Chicago, IL, USA; the 2014 Annual Meeting of the European Society of Medical Oncology, September 26th to September 30th, Madrid, Spain; the 2015 Global Congress on Prostate Cancer, February 4th to February 6th, Rome, Italy; and the 2015 Annual Meeting of the American Society of Clinical Oncology Genitourinary Cancers Symposium, February 26th to February 28th, Orlando, FL, USA.

**Author contributions:** Christopher C. Parker had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Parker, Bruland, Vogelzang, Nilsson, Sartor.

Acquisition of data: Parker, Finkelstein, O’Sullivan, Vogelzang, Nilsson, Bottomley.

Analysis and interpretation of data: Parker, Michalski, O’Sullivan, Bruland, Vogelzang, Coleman, Nilsson, Sartor, Li, Seger.

Drafting of the manuscript: Parker, Michalski, Vogelzang, Coleman, Nilsson, Sartor.

Critical revision of the manuscript for important intellectual content: Parker, Finkelstein, O’Sullivan, Bruland, Vogelzang, Coleman, Nilsson, Sartor, Li, Seger, Bottomley.

Statistical analysis: Li.

Obtaining funding: None.

Administrative, technical, or material support: None.

Supervision: None.

Other (review and approval of final manuscript): Parker, Finkelstein, Michalski, O’Sullivan, Bruland, Vogelzang, Coleman, Nilsson, Sartor, Li, Seger, Bottomley.

Financial disclosures: Christopher C. Parker certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultan- cies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Parker has received grants or funding to his institution from Bayer, has served as a consultant for BNIT, and has received honoraria from Bayer and Janssen. Finkelstein has served as a consultant for Bayer. O’Sullivan has received grants or funding from Bayer and has served as a consultant for and received honoraria from Bayer, Astellas, and Janssen. Bruland has served as a consultant (uncompensated) for Bayer and has had patents filed. Vogelzang has received grants or funding to his institution from Bayer AS (formerly Algeta ASA) and Bayer, has received honoraria from Bayer, BMS, Sanofi Aventis, Medivation, Endocyte, and Dendreon, and has a stock ownership or options interest in Caris. Coleman has received grants or funding to his institution from Bayer. Nilsson has served as a consult- ant for Bayer. Li and Seger are employed by Bayer HealthCare Pharmaceuticals. Bottomley has received grants or funding to his institution from, has served as a consultant for, and has received honoraria from Bayer.

Funding/Sponsor and role of the sponsor: ALSYMPCA was funded by Bayer AS (formerly Algeta ASA) and Bayer HealthCare Pharmaceuticals, and supported by the National Institute for Health Research Royal Marsden and Institute for Cancer Research Biomedical Research Centre. Employees of Bayer AS and Bayer HealthCare Pharmaceuticals participated in the study design and conduct and were involved in collection, management, analysis and interpretation of the data, and preparation, review, and approval of the manuscript. Heather Nyce, PhD, of SciStrategy Communications provided manuscript writing support, funded by Bayer HealthCare Pharmaceuticals.

Acknowledgments: The authors thank the patients who participated in ALSYMPCA and the clinical and research staff members who cared for them at all participating centers.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.eururo.2016.06.002.

References


